World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Liu Chen Kiow J, Hoang T, Bedi HK, Majdzadeh Ardekani Z, Rosenfeld D, Reise-Filteau M, Bressler B, Leung Y, Rosenfeld G. Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2024; 30(46): 4904-4913 [PMID: 39679312 DOI: 10.3748/wjg.v30.i46.4904]
URL:	https://www.wjgnet.com/1007-9327/full/v30/i46/4904.htm

(115) (115) (0) (0) (0) (20) (3886) (10)

Number	Citing Articles
1	Mahmoud H. Mosli, Badr Al-Bawardy, Turki AlAmeel, Nahla A. Azzam, Shakir A. Bakkari, Othman R. Alharbi, Abdulelah Almutairdi, Yaser K. Meeralam, Omar I. Saadah, Majid A. Almadi, Waleed Alhazzani, Haifa F. Alotaibi, Khalidah A. Alenzi, Bedor A. Al-Omari, Hajer Y. Almudaiheem, Ahmed H. Al-Jedai. Practical guidelines on medical management of adults with moderate-to-severe inflammatory bowel disease. Saudi Journal of Gastroenterology 2026; 32(4) doi: 10.4103/sjg.sjg_277_25
2	Polu Picheswara Rao, Manish Vyas. Drug-disease interactions in inflammation: mechanisms, clinical Impact, and future directions. Inflammopharmacology 2026; 34(3) doi: 10.1007/s10787-026-02128-2
3	Shuroog Nabhan, Hesham Qary, Abdullah Ajwah, Bassam Alsaeedi, Yazeed Ajwa, Sara Alhashmi, Alia Hijazi, Jomana Akbar, Maha Asiri. Switching Between Reference Adalimumab and Biosimilars in Adult Patients With Inflammatory Bowel Disease: A Systematic Literature Review. Cureus 2026; doi: 10.7759/cureus.110943
4	Daniel Himelstein, Megan McNicol, Mahmoud Abdel‐Rasoul, Brendan M. Boyle, Hilary K. Michel, Ross Maltz. Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease. JPGN Reports 2026; doi: 10.1002/jpr3.70212
5	Vannessa Duarte, Tomas Gabriel Bas. Advances in Biosimilars: A Systematic Review of Machine Learning Applications. Pharmaceuticals 2026; 19(5) doi: 10.3390/ph19050745
6	Cristiano S Moura, Albert Etingin, Luck Lukusa, Harminder Singh, Neeraj Narula, Laura E Targownik, Yvette Leung, Petros Zezos, Beata Polewiczowska-Nowak, Waqqas Afif, Sasha Bernatsky. Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. World Journal of Gastroenterology 2026; 32(9): 114580 doi: 10.3748/wjg.v32.i9.114580 Abstract(120) \| Core Tip(109) \| Full Article(HTML)(593) \| Full Article (PDF)-1187K(154) \| Full Article with Cover (PDF)-2568K(65) \| Full Article (XML)-109K(40) \| Audio-512K(22) \| Peer-Review Report-223K(56) \| Answering Reviewers-213K(49) \| Supplementary Material-364K(45) \| Times Cited (2) \| Total Visits (992) \| Open
7	Mark Harrison, Sandra Blitz, Michael Law, Mina Tadrous, Tara Gomes, Fiona Clement, Greg Rosenfeld, Aslam Anis, Nick Bansback. The Longer‐Term Impact of Biosimilar Switching Policies in Patients With Inflammatory Bowel Disease in British Columbia, Canada: A Retrospective, Population‐Based Study. Pharmacoepidemiology and Drug Safety 2026; 35(6) doi: 10.1002/pds.70395
8	Sara Ben Youssef, Amal Trabelsi, Karim Boudiaf, Nabil Jebali. Real-World Evidence for Biosimilar Interchangeability Across Therapeutic Areas. International Journal of Pharmaceutical Research and Allied Sciences 2025; 14(4) doi: 10.51847/DE3fVS8xuc
9	Justin Kritzinger, Ivanna Candel, Gynter Kotrri, Huzaifa Nadeem, Waqqas Afif, Alain Bitton, Gary Wild, Talat Bessissow, Peter Laszlo Lakatos. Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World Journal of Gastroenterology 2025; 31(48): 114355 doi: 10.3748/wjg.v31.i48.114355 Abstract(159) \| Core Tip(122) \| Full Article(HTML)(999) \| Full Article (PDF)-605K(125) \| Full Article with Cover (PDF)-878K(142) \| Full Article (XML)-118K(59) \| Audio-362K(32) \| Peer-Review Report-244K(48) \| Answering Reviewers-253K(56) \| Times Cited (6) \| Total Visits (1475) \| Open
10	Yan Wu, Fang Zhao, Juan Zhao, Rong-Yao Ruan, Fei-Yan Wu, Yusheng Xu. Study on the effect of Portulaca oleracea L. extract on chronic ulcerative colitis in rats induced by allogeneic antigen and acetic acid. Acta Cirúrgica Brasileira 2026; 41 doi: 10.1590/acb412126
11	Qin-Jian Wang, Zheng Zhu, Guang-Rong Lu. Letter to the Editor: Missing mechanistic data and small inflammatory bowel disease cohorts: Key barriers in ustekinumab switching. World Journal of Gastroenterology 2026; 32(19): 117160 doi: 10.3748/wjg.v32.i19.117160 Abstract(132) \| Core Tip(97) \| Full Article(HTML)(443) \| Full Article (PDF)-356K(239) \| Full Article with Cover (PDF)-835K(59) \| Full Article (XML)-55K(35) \| Audio-798K(7) \| Peer-Review Report-242K(45) \| Answering Reviewers-82K(42) \| Times Cited (0) \| Total Visits (776) \| Open

Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.